Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Laboratory Corporation of America Holdings    LH

Real-time Quote. Real-time Cboe BZX - 04/25 04:36:08 pm
171.405 USD   +3.21%
03:32pLABORATORY CORP : LH) reported earnings of $2.78 per share beating W..
AQ
01:22pLABCORP : 1Q Earnings Snapshot
AQ
01:07pLABORATORY OF A : LabCorp Announces Strong 2018 First Quarter Result..
BU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Laboratory Corp. of America Holdings : LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2012 | 10:05pm CEST

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2012 to September 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 7, 2012, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.50 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 26, 2012. The payment of contingent cash interest is expected to be made on September 11, 2012.

About LabCorp®

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its specialized labs and the LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2011, and subsequent SEC filings.

LabCorp
Stephen Anderson, 336-436-5274
www.labcorp.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LABORATORY CORPORATION OF
03:32pLABORATORY CORP. OF AMERICA (NYSE : LH) reported earnings of $2.78 per share bea..
AQ
01:22pLABCORP : 1Q Earnings Snapshot
AQ
01:08pLABORATORY CORP OF AMERICA HOLDINGS : Financial Statements and Exhibits (form 8-..
AQ
01:07pLABORATORY CORP OF AMERICA HOLDINGS : Results of Operations and Financial Condit..
AQ
01:07pLABORATORY OF AMERICA : LabCorp Announces Strong 2018 First Quarter Results and ..
BU
01:03pLABORATORY CORPORATION OF AMERICA HO : to Host Earnings Call
AC
04/24LABORATORY OF AMERICA : LabCorp and Mount Sinai Health System Enhance Laboratory..
BU
04/24WALGREENS BOOTS ALLIANCE : Pilot Program in Gainesville, Fla., Features New Appr..
AQ
04/24LABORATORY OF AMERICA : LabCorp at Walgreens Expands into Florida; Ten new patie..
AQ
04/23LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
AQ
More news
News from SeekingAlpha
09:48aLabCorp Q1 revenues up 18%; non-GAAP EPS up 31%; raises revenue guidance 
07:04aLaboratory Corporation of America beats by $0.15, beats on revenue 
04/24Notable earnings before Wednesday?s open 
04/14Medpace Holdings Facing Some Challenges To A Model That Has Worked Well 
03/23Premarket analyst action - healthcare 
Financials ($)
Sales 2018 11 467 M
EBIT 2018 1 738 M
Net income 2018 968 M
Debt 2018 5 554 M
Yield 2018 -
P/E ratio 2018 17,54
P/E ratio 2019 16,10
EV / Sales 2018 1,97x
EV / Sales 2019 1,82x
Capitalization 16 995 M
Chart LABORATORY CORPORATION OF
Duration : Period :
Laboratory Corporation of  Technical Analysis Chart | LH | US50540R4092 | 4-Traders
Technical analysis trends LABORATORY CORPORATION OF
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 194 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
David P. King Chairman, President & Chief Executive Officer
Glenn A. Eisenberg Chief Financial Officer, Treasurer & Executive VP
Mark Elliott Brecher Chief Medical Officer & Senior Vice President
Lance V. Berberian Chief Information Officer & Senior Vice President
Marcia T. Eisenberg Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
LABORATORY CORPORATION OF AMERICA HOLDINGS4.12%16 995
HCA HOLDINGS (HOSPITAL CORPORATION AMERICA)10.31%34 130
FRESENIUS MEDICAL CARE-5.70%30 605
QUEST DIAGNOSTICS0.97%13 507
DAVITA-13.01%11 482
UNIVERSAL HEALTH SERVICES5.99%11 331